| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6344211 | PURDUE PHARMA LP | Transdermal absorption of active substances from subcooled melts |
Dec, 2015
(8 years ago) | |
| US6264980 | PURDUE PHARMA LP | Transdermal resorption of active substances from supercooled masses of levulic acid |
Dec, 2015
(8 years ago) | |
| USRE41408 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorpine |
Sep, 2017
(6 years ago) | |
| USRE41489 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorphine |
Sep, 2017
(6 years ago) | |
| USRE41571 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorphine |
Sep, 2017
(6 years ago) | |
| US9642850 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorphine |
Sep, 2017
(6 years ago) | |
Butrans is owned by Purdue Pharma Lp.
Butrans contains Buprenorphine.
Butrans has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Butrans are:
- US6344211
- US6264980
- USRE41408
- USRE41489
- USRE41571
- US9642850
Butrans was authorised for market use on 30 June, 2010.
Butrans is available in film, extended release;transdermal dosage forms.
Butrans can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The generics of Butrans are possible to be released after 13 October, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-250) | Oct 13, 2020 |
| New Dosage Form(NDF) | Jun 30, 2013 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 June, 2010
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
BUTRANS family patents
